ATAI · AtaiBeckley Inc.
$7.35
+0.00% last session
End-of-day data · close of 2026-09-10
Market cap
$3B
Enterprise value
$3B
Trailing P/E
—
Forward P/E
-15.0
Dividend yield
—
Beta
1.55
Avg volume
14M
Employees
0K
Daily Change %
0.00%
5 Days Change
-1.35%
10 Days Change
-0.68%
30 Days Change
1.11%
60 Days Change
41.01%
Month to Day Change
-0.68%
Year to Day Change
78.24%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ATAI
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-12
Latest call per bank · past 12 months
Deutsche Bank
Hold$8.00
+8.8% vs priceJefferies
Hold$7.50
+2.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-12 | Deutsche Bank | Downgrade | Buy → Hold | $12.00 → $8.00 |
| 2026-07-20 | HC Wainwright & Co. | Downgrade | Buy → Neutral | $25.00 → $7.50 |
| 2026-07-17 | Guggenheim | Downgrade | Buy → Neutral | $0.00 |
| 2026-07-17 | Jones Trading | Downgrade | Buy → Hold | $0.00 |
| 2026-07-17 | Jefferies | Downgrade | Buy → Hold | $10.00 → $7.50 |
| 2026-07-16 | Maxim Group | Downgrade | Buy → Hold | $0.00 |
| 2026-07-16 | Canaccord Genuity | Downgrade | Buy → Hold | $0.00 → $8.00 |
| 2026-07-16 | Needham | Downgrade | Buy → Hold | $0.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-10
- RSI (14): RSI is 62 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 7.3% above the 50-day MA ($6.85).
- Price vs 200-day MA: Trading 55.7% above the 200-day MA ($4.72).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.05) — short-term momentum is fading.
- 52-week range: Price is within 5% of the 52-week high ($7.44).
ATAI Price Chart
Loading chart for ATAI…
Fundamentals
About AtaiBeckley Inc.
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.